• Hypertrophic Cardiomyopathy (HCM)
  • Eyecare
  • Urothelial Carcinoma
  • Hemophilia
  • Heart Failure
  • Vaccines
  • Neonatal Care
  • Type II Inflammation
  • Substance Use Disorder
  • Gene Therapy
  • Lung Cancer
  • Spinal Muscular Atrophy
  • HIV
  • Post-Acute Care
  • Liver Disease
  • Asthma
  • Atrial Fibrillation
  • COVID-19
  • Cardiovascular Diseases
  • Prescription Digital Therapeutics
  • Reproductive Health
  • The Improving Patient Access Podcast
  • Blood Cancer
  • Ulcerative Colitis
  • Respiratory Conditions
  • Multiple Sclerosis
  • Digital Health
  • Population Health
  • Sleep Disorders
  • Biosimilars
  • Plaque Psoriasis
  • Leukemia and Lymphoma
  • Oncology
  • Pediatrics
  • Urology
  • Obstetrics-Gynecology & Women's Health
  • Opioids
  • Solid Tumors
  • Autoimmune Diseases
  • Dermatology
  • Diabetes
  • Mental Health

Obama and Daschle want your reform wish list


Healthcare leaders are concerned about future public programs under the new administration that simply shift costs

If you attended a meeting, I'd love to hear what happened. Send me an email.

Several managed care leaders I've spoken to lately told me what they want from the new administration's official healthcare reform team.

Spend a fortune getting everyone's diabetes under control, then turn them away from coverage for six months, and then bring them back again? Were you really expecting a return on that investment? Those now worse-off patients are yours once again, and you get to start over, thanks to your cumbersome eligibility process that's meant to save money by keeping your rolls short. Someone needs to measure this alleged savings.

What's on your wish list? Daschle wants to know.

Julie Miller is editor-in-chief of MANAGED HEALTHCARE EXECUTIVE. She can be reached at julie.miller@advanstar.com

Related Content
© 2023 MJH Life Sciences

All rights reserved.